Despite much attention being focused on the blood components of the coagulation system in APS patients, we think that in the presence of antiphospholipid antibodies (aPL), endothelial cells may show some changes to unclothe the anticoagulant state and promote the process of hypercoagulation.
MATERIALS AND METHODS

Patients
Five patients from outpatient clinics of the Rheumatology Division, Kaohsiung Medical University Hospital, who fulfilled classification criteria for APS (Sapporo criteria [3] ) were enrolled in the study. All patients were either positive for LA, aCL or anti-β2-glycoprotein-1 (β2-GP-1). The age of the five patients ranged from 20 to 44 years (mean, 27 years) ( Table 1 ). This study was approved by the medical ethics committee of Kaohsiung Medical University Hospital, and all patients signed a consent form.
Purification of IgG
Immunoglobulin G (IgG) was isolated from the sera of APS patients by protein G sepharose (Amersham, Uppsala, Sweden). The protein concentration of the purified antibodies was determined by Bradford assay and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The isolated IgG was further concentrated by the use of Amicon Ultra-4 (Millipore Corp., Billerica, MA, USA) with centrifugation at 4000 g for 10 minutes. The concentrate was then filtered by 0.22 μm microporous membrane (Millipore Corp.) to make it sterile.
Cells
Human umbilical vein endothelial cells (HUVECs) were isolated from the umbilical veins of normal term deliveries as described previously [17] . Briefly, the vein was rinsed with phosphate-buffered saline (PBS) and then with Hank's balanced salt solution (Sigma Chemical Co., St Louis, MO, USA) through 19-gauge drawing-up needles secured into the vein. Then, 0.1% collagenase Type IV (Sigma Chemical Co.) was introduced into the umbilical vein and the cord was submerged in warm cord buffer and incubated at 37°C in a humidified 5% CO 2 at atmosphere for 15 minutes. The collagenase solution containing HUVECs was aspirated from the vein, and centrifuged twice at 1,000 rpm for 5 minutes. HUVECs contained in this pellet were resuspended in Iscove's Modified Dulbecco's Medium (Biological Industries Ltd., Kibbutz Beit Haemek, Israel) containing 10 μg/mL of endothelial cell growth supplement (Upstate Biotechnology Inc., Lake Placid, NY, USA), 10% fetal calf serum (Biological Industries Ltd.), 10 μg/mL of insulin (Sigma Chemical Co.), and 33 mM 3-isobutyl-1-methylxanthine (Sigma Chemical Co.), 0.1% antibiotics (penicillin, streptomycillin, amphotericin). HUVECs were then seeded into a sterile 75 cm 2 culture flask (NUNC A/S, Roskilde, Denmark)
that had been coated with 0.8% gelatin (Merck, Darmstadt, Germany). The culture medium was changed every other day and the culture continued in a humidified 5% CO 2 atmosphere until 80% confluence was reached. HUVECs were only used from passages 2-3 in this study.
Flow cytometry
HUVECs were seeded at 4˜10 5 cells/mL density on 48-well plates (Costar/Corning, Acton, MA, USA) for flow cytometry. After the 6-hour treatment of APS IgG (1 mg/mL), cells were harvested and washed in PBS. After resuspension in 100 μL of annexin V binding buffer (10 mmol/L HEPES, 140 mmol/L NaCl, 2.5 mmol/L CaCl 2 , pH 7.4; Molecular Probes Inc., Table 2) .
RESULTS
Changes in cell membrane phospholipids
When HUVECs were cultured in the presence of IgG isolated from the five patients, the cell membrane expressed more negatively charged phospholipids in their outer layers, which was represented by stronger annexin V binding. In addition, the negative staining of the cells by propidium iodide indicated that the nuclear membranes were still intact ( Figure 1 , Table 2 ).
Expression of adhesive molecules
To test whether the endothelial cells were activated by the antibodies, we further analyzed the expression of the adhesion molecule ICAM-1 on the cell surface when the cells were exposed to IgG isolated from the patients. All five IgGs isolated from the patients increased the surface expression of ICAM-1 ( Figure 2 , Table 2 ). Events Events 
Figure 1. Effects of antiphospholipid antibody-containing immunoglobulin G (IgG) purified from antiphospholipid syndrome (APS) patients on: (A) annexin V expression; and (B) cell viability detected by flow cytometry. (A) After incubation of human umbilical vein endothelial cells with IgG isolated from five patients with APS, the expression of negatively charged phospholipids on the cell surface increased, which was detected by increased annexin V-fluorescein isothiocyanate binding. (B) At the same time, the intact nuclear membrane, detected by propidium iodide, denotes that the cells are still alive.
DISCUSSION
APS is characterized by hypercoagulation. Besides the influence of antibodies on the blood components including coagulation factors, cofactors, protein C and protein S have been reported in many papers [18, 19] . We thought that antibodies might trigger the procoagulant components of endothelial cells and hence start the coagulation cascade. Our study found that when exposed to IgGs, the cell membrane began to increase the expression of negatively charged phospholipid on their outer layers. There are two possibilities when a cell has increased expression of negatively charged phospholipids on the cell membrane but has an intact nuclear membrane: apoptosis and cell activation. When apoptosis begins, the first sign is cell membrane flipping the inner layer of phospholipid bilayers out [20] . When the condition deteriorates, the cell membrane would further disrupt and encircle some cytoplasmic content to produce apoptotic bodies. On the other hand, when endothelial cells are activated, they express adhesive molecules for further interaction with intravascular cells such as white blood cells and platelets [18] . In our experiment, the increased expression of ICAM-1 on HUVECs in addition to membrane flipping indicated that the cells were activated and not in an apoptotic state. However, the possibility exists that after cell activation, the endothelial cell may progress to cell death, the so-called "activation-induced cell death". No matter what happens after cell activation, negatively charged phospholipids are already exposed, and the increased negative charge on the cell surface is the key factor initiating the intrinsic pathway of the coagulation system, and the high affinity of β2-GP-1 to negatively charged phospholipids is considered to be the triggering mechanism for the development of anti-β2-GP-1, which is specific for autoimmune disease associated APS [21, 22] .
There are a variety of aPL. The epitopes of target antigens vary among different clones of antibodies. Some patients' antibodies are reactive only with cardiolipin, while others react with reagents of Venereal Disease Research Laboratory, LA, and even with some coagulation factors [23] [24] [25] . Antibodies are not always cross-reactive. Based on high heterogeneity of antigens, it is not possible to purify these antibodies by using a single antigen such as cardiolipin. As in many other reports, we used purified IgG from APS patients as the source of aPL [26] [27] [28] . The limitation of our study is that no healthy control serum or IgG was used. In another experiment, however, we found that when IgG from patients and antiphospholipid monoclonal antibodies were compared, IgG from normal controls had no impact on endothelial cells in the expression of procoagulant-anticoagulant molecules such as thrombomodulin, or von Willebrand factor (paper in submission). We believe that the above changes are specific.
Many surface components of endothelial cells, such as thrombomodulin, protein C, and von Willebrand factor, are involved in the balance between anticoagulation and thrombosis [29] [30] [31] [32] [33] . Further work must be done to clarify which factors play critical roles after the impact of antibodies on endothelial cells and, if possible, to characterize the different targets among different clones of antibodies. Above all, we conclude that apart from the alteration of blood components after reaction with antibodies, endothelial cells also take part in the initiation of thrombosis when exposed to antibodies. 
